

femme**pharma**

Healthcare products developed
by women, for women

Investment Opportunity

Prescription



The Opportunity

Women in the US are looking for relief from multiple chronic conditions. FemmePharma Global Healthcare is leveraging their proprietary and validated regional Drug Delivery technology platform to meet these needs.

PARDEL™

Intravaginal delivery of active drug to the pelvic region.

DERMODEL™

Transdermal delivery of active drug without the use of a patch or device.

TVDT™

Transvaginal dispersal technology, regional delivery.

An Unmet Need

There are treatment options available for the conditions we are focused on. Our differentiation is Targeted Drug Delivery specific to the area of disease. This promotes the confinement of the drug in the area of the body affected by disorder.

The benefits of regional delivery:

1. Lower volume, lower concentration of the active drug
2. Alleviates and may eliminate many of the side effects associated with systemic delivery

Our Pipeline

We are developing a set of prescription pharmaceutical products which effectively addresses unmet needs.

1. **FP1199:** Phase 3 ready; for Endometriosis (Pardel)
2. **FP1097:** Phase 3 ready; for Urinary Incontinence (Pardel)
3. **FP1198:** Phase 2 completed; for Pain Associated with Fibrocystic Breast Disease (Dermodel)

In Keeping with Our Mission

As a company that is dedicated to enhancing the quality of life for women through the development of novel, esthetically elegant products using scientific expertise and the highest quality pharmaceutical industry standards, we are uniquely qualified to solve these problems.

Our science is by women, for women.

Our USP

Our unique selling proposition is simple yet elegant. Our pipeline products all follow our core principle of regional delivery with minimal to no side effects. These solutions have proven effective in recent clinical studies while reporting significant improvement over current treatments.

Target Market

All of our pipeline products are targeted toward large yet highly specific markets. These markets provide us the ability to replace currently used products by improving them.



1 IN 5 WOMEN SUFFER FROM FIBROCYSTIC BREAST DISEASE



1 IN 6 WOMEN SUFFER FROM OVERACTIVE BLADDER



1 IN 20 WOMEN SUFFER FROM ENDOMETRIOSIS



To learn more:
Request a meeting with our CEO by
emailing investrx@femmepharma.com

femmepharma

www.femmepharma.com